Real-world healthcare costs and resource utilization in patients with von Willebrand disease and angiodysplasia.
Nathan T ConnellJorge CaicedoN NietoSagnik ChatterjeeA HaitA K GuptaMichael BullanoBob G SchultzPublished in: Expert review of pharmacoeconomics & outcomes research (2023)
Despite recent therapeutic advances, there is room for considerable reduction of the disease burden in patients with VWD and angiodysplasia.
Keyphrases